Literature DB >> 17504884

Risk factors for early visual deterioration in temporal arteritis.

Tobias Loddenkemper1, Pankaj Sharma, I Katzan, Gordon T Plant.   

Abstract

BACKGROUND: Despite corticosteroid treatment, patients with temporal arteritis may continue to lose vision. However, predictors of progressive visual loss are not known.
METHODS: We retrospectively reviewed 341 consecutive patients with suspected temporal arteritis who underwent temporal artery biopsy. 90 patients with biopsy proven temporal arteritis were included in our study.
RESULTS: Twenty-one patients (23%) experienced continuous visual symptoms despite steroid therapy and 14 among these suffered persistent visual deterioration. Based on univariate analysis, visual loss on presentation was associated with disc swelling and a history of hypertension. Risk factors for progressive visual loss included older age, elevated C reactive protein and disc swelling.
CONCLUSION: Although corticosteroid therapy improves the visual prognosis in temporal arteritis, steroids may not stop the progression of visual loss. Our study reliably establishes the risk factors for visual loss in this serious condition. Whether addressing these risk factors early in their presentation can alter the visual outcome remains unknown. Individual risk anticipating treatment regimens and strategies might improve the visual prognosis in temporal arteritis in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504884      PMCID: PMC2117585          DOI: 10.1136/jnnp.2006.113787

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  45 in total

1.  Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.

Authors:  G G Hunder; S G Sheps; G L Allen; J W Joyce
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

3.  Neurologic disease in biopsy-proven giant cell (temporal) arteritis.

Authors:  R J Caselli; G G Hunder; J P Whisnant
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

4.  Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy.

Authors:  M J Kupersmith; R Langer; H Mitnick; R Spiera; H Spiera; M Richmond; S Paget
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

Review 5.  Deterioration of giant cell arteritis with corticosteroid therapy.

Authors:  H Staunton; F Stafford; M Leader; D O'Riordain
Journal:  Arch Neurol       Date:  2000-04

6.  The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications.

Authors:  B A Bengtsson; B E Malmvall
Journal:  Arthritis Rheum       Date:  1981-07

7.  Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.

Authors:  K A Huston; G G Hunder; J T Lie; R H Kennedy; L R Elveback
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

8.  Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis.

Authors:  O Rauzy; M Fort; F Nourhashemi; L Alric; H Juchet; M Ecoiffier; M Abbal; D Adoue
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

9.  Prevention of blindness in giant cell arteritis by corticosteroid treatment.

Authors:  A B Myles; T Perera; M G Ridley
Journal:  Br J Rheumatol       Date:  1992-02

10.  Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients.

Authors:  W L Chmelewski; K M McKnight; C A Agudelo; C M Wise
Journal:  Arch Intern Med       Date:  1992-08
View more
  10 in total

1.  Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.

Authors:  M Yates; Y K Loke; R A Watts; A J MacGregor
Journal:  Clin Rheumatol       Date:  2013-09-12       Impact factor: 2.980

Review 2.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

Review 3.  Giant cell arteritis: a review.

Authors:  Pravin Patil; Niral Karia; Shaifali Jain; Bhaskar Dasgupta
Journal:  Eye Brain       Date:  2013-03-09

4.  Preserved Visual Acuity in Anterior Ischemic Optic Neuropathy Secondary to Giant Cell (temporal) Arteritis.

Authors:  Aileen A Antonio-Santos; Sally J Murad-Kejbou; Rod Foroozan; Sunita Yedavally; David I Kaufman; Eric R Eggenberger
Journal:  J Vasc Interv Neurol       Date:  2016-01

Review 5.  [Vasculitis. Treatment outcome parameters].

Authors:  P M Aries; A Gause
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 6.  Neuro-ophthalmic complications in giant cell arteritis.

Authors:  Frances A Borg; Victoria L J Salter; Bhaskar Dasgupta
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 7.  Giant Cell Arteritis: Beyond Corticosteroids.

Authors:  Lauren Steel; Asad Khan; Bhaskar Dasgupta
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

8.  Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study.

Authors:  Gunnar Tomasson; Christine Peloquin; Aladdin Mohammad; Thorvardur J Love; Yuqing Zhang; Hyon K Choi; Peter A Merkel
Journal:  Ann Intern Med       Date:  2014-01-21       Impact factor: 25.391

Review 9.  Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis.

Authors:  James A Prior; Hoda Ranjbar; John Belcher; Sarah L Mackie; Toby Helliwell; Jennifer Liddle; Christian D Mallen
Journal:  BMC Med       Date:  2017-06-28       Impact factor: 8.775

10.  The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population.

Authors:  Max Yates; Karly Graham; Richard Arthur Watts; Alexander James MacGregor
Journal:  BMC Musculoskelet Disord       Date:  2016-07-15       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.